Last reviewed · How we verify
Placebo To Match Oseltamivir Phosphate
Oseltamivir phosphate is a prodrug that is metabolized into its active form, which is a selective inhibitor of the influenza virus neuraminidase.
Oseltamivir phosphate is a prodrug that is metabolized into its active form, which is a selective inhibitor of the influenza virus neuraminidase. Used for Treatment and prophylaxis of influenza A and B in patients 1 year and older.
At a glance
| Generic name | Placebo To Match Oseltamivir Phosphate |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Neuraminidase inhibitor |
| Target | Neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The active form of oseltamivir phosphate binds to the neuraminidase protein on the surface of influenza viruses, preventing the release of new viral particles from infected cells. This action helps to reduce the spread of the virus within the body and alleviate symptoms of influenza.
Approved indications
- Treatment and prophylaxis of influenza A and B in patients 1 year and older
Common side effects
- Nausea
- Vomiting
- Headache
- Fatigue
- Diarrhea
Key clinical trials
- Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza (PHASE3)
- Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects (PHASE1)
- Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo To Match Oseltamivir Phosphate CI brief — competitive landscape report
- Placebo To Match Oseltamivir Phosphate updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI